Komori
Terumo (4543) · RiskReframed

TCFD Management of Climate Change Risks and Opportunities and GHG Reduction Targets

First written in FY2022. 2 of 5 entries say "Advanced", first in FY2024. Latest entry: FY2026.

5entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2023 – FY20252022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
TCFD Analysis and Supply-Chain GHG Reduction TargetsA theme 6 companies write about · 2 as a headwind · 4 as a tailwind

Terumo moved to the "Worse" side of this theme in 2026.

0 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「The following disclosures address responses to climate- and nature-related risks and opportunities based on the TCFD (Task Force on Climate-related Financial Disclosures) and TNFD (Taskforce on Nature-related Financial Disclosures) frameworks.」

    Expanded its previous climate change and TCFD management framework into environmental management encompassing nature-related risks, biodiversity and the TNFD. In April 2025, it established a statement on nature and conducted an initial assessment in FY2024 of dependence on and impacts on nature across the entire value chain.
  2. FY2025AdvancedAnnual report

    「Renewable energy use in electricity consumption: usage rate 50% (FY2030); 37.5% (Note 2)」

    The company maintained its targets of reducing Scope 1+2 emissions by 50.4% by FY2030, achieving a 50% renewable energy share and reaching carbon neutrality by FY2040, and disclosed FY2024 actual results of a 26.8% reduction in emissions and a 37.5% renewable energy usage rate.
  3. FY2024AdvancedAnnual report

    「CO2 emissions (Scope 1+2, versus FY2018): reduction rate 50.4% (FY2030); reduction rate 100% (FY2040); 21.7% reduction (Note 2); renewable energy use in electricity consumption: 50% (FY2030); 32.1%」

    For climate change action, the company maintained its targets of a 50.4% reduction in Scope 1+2 emissions by FY2030, a 50% renewable energy share and carbon neutrality by FY2040, and disclosed actual results including a 21.7% reduction in emissions and a 32.1% renewable energy usage rate.
  4. FY2023RaisedAnnual report

    「Reduce greenhouse gas emissions by 50.4% from FY2018 levels by FY2030; achieve a 50% renewable energy share in electricity consumption by FY2030; achieve carbon neutrality by FY2040」

    For climate change action, the company raised its Scope 1+2 reduction target for FY2030 from 30% to 50.4%, and specified a 50% renewable energy share and carbon neutrality by FY2040. It also disclosed a target of reducing Scope 3 emissions per unit of revenue by 60%.
  5. FY2022First statedAnnual report

    「We aim to reduce Scope 1+2 GHG emissions by 30% from FY2018 levels by FY2030, and Scope 3 GHG emissions per unit of revenue by 60% from FY2018 levels by FY2030. These targets have also been certified by the international organization Science Based Targets initiative (SBT initiative) as being based on scientific evidence.」

    For climate change, the company made its first comprehensive disclosure of governance based on the TCFD framework, 4°C and 1.5°C scenario analyses, physical and transition risks, and opportunities. It set FY2030 reduction targets for Scope 1+2 and Scope 3 and received SBT certification.
Moved together

"Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333333★123456
  1. ★This thread
  2. 1Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets3×
  3. 2Becoming a Company with a Strong Global Presence and Achieving Sustainable, Profitable, High-Quality Growth3×
  4. 3Expanding market share in global markets and enhancing brand value3×
  5. 4Global sales expansion of cardiovascular products such as Ultimaster3×
  6. 5High-value-added products and services that contribute to reducing patients’ financial burden, improving medical safety, and enhancing operational efficiency3×
  7. 6Strengthening Cost Competitiveness Through Products Tailored to Regional Needs and a Global Production Network3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Terumo yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
TCFD Management of Climate Change Risks and Opportunities and GHG Reduction Targets | TERUMO CORPORATION (4543) | Komori